The breast lesion localization market size was valued at USD 0.54 billion in 2023 and is projected to grow from USD 0.58 Billion in 2024 to USD 1.0222 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.21% during the forecast period (2024 - 2032). The increase in breast cancer cases worldwide and the favorable reimbursement practices in developed economies are the main market drivers of the market expansion for breast lesion localization techniques.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market for breast lesion localization techniques is expanding as a result of the rising incidence of breast cancer in the world. According to a research released by the World Health Organisation, 685,000 people died worldwide and 2.3 million women were diagnosed with breast cancer in 2020. Technology developments in breast lesion localization techniques and rising public awareness of early identification and treatment of breast cancer contribute to the market's expansion. Additionally, the development of precise, affordable, and safe advanced gadgets is assisting the expansion of the market's revenue.
Furthermore, there is an increasing need for breast lesion localization techniques as awareness of the value of routine breast cancer screening and early detection grows. According to the National Cancer Institute (NCI), breast cancer is the most common type of cancer in American women, with an anticipated 281,550 new cases in 2023. Early detection of breast cancer by screening methods, such as mammography and breast lesion localization, can enhance results and lower mortality rates. The market is expanding as a result of breast cancer screening programs being implemented by governments and healthcare organizations globally.
Additionally, the demand for the breast lesion localization devices, which are used to identify and map breast cancer, is rising. To far, only a small number of producers and companies are active in the production of breast lesion localization devices. The market for breast lesion localization offers substantial growth potential for numerous other small and major producers. Breast cancer is the most prevalent disease affecting women worldwide, both in industrialized and developing nations. Early breast cancer mapping and detection can improve a patient's recovery ability without specific drugs. Therefore, breast cancer treatment depends greatly on the early discovery of the disease. Additionally, the government is putting together programmes to raise public knowledge of breast cancer and do away with the stigma attached to its signs, symptoms, and treatments. Therefore, during the anticipated time, these elements are creating chances for the growth of the breast lesion localization market revenue.
The market segmentation of breast lesion localization, based on type includes Wire-Guided Localization, Radioactive Seed Localization, Non-Radioactive Radar Localization, and Magnetic Seed. The radioactive seed localization segment dominated the market. Due to its growing use in the treatment of malignant cells, particularly breast cancer, radioisotope localization is growing in popularity. This method uses a radioisotope, which, when handled appropriately, harms the surrounding tissue the least. Before removal surgery, a radioisotope is injected into the centre of the target. This allows the surgeon to accurately pinpoint and remove the lesion location, which is boosting this segment's revenue.
The breast lesion localization market segmentation, based on usage, includes Tumor Identification and Sentinel Lymph Node Identification. The sentinel lymph node identification category generated the most income. Sentinel lymph node biopsy is used more frequently than traditional procedures because it is more sensitive, accurate, and causes less morbidity. Moreover, segment growth is anticipated to be boosted in the future by combination localization for sentinel lymph node and non-palpable tumors.
Figure 1: Breast Lesion Localization Market, by Usage, 2022 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market segmentation of breast lesion localization, based on end user, includes Hospitals and Clinics and Ambulatory Surgical Centers. The hospitals and clinics category generated the most income due to the availability of long-term care facilities, the scheduling of surgeries, and the presence of educated medical professionals. Additionally, the development of cancer speciality hospitals, decreased treatment costs, and an increase in cancer cases worldwide contribute to this segment's revenue growth.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American breast lesion localization market area will dominate this market due to the high prevalence of breast cancer. In the United States, breast cancer is the most common cancer among women. Each year, 29% of women are given a cancer diagnosis, according to the National Centre for Biotechnology Information. For the treatment of breast cancer, a number of prestigious businesses are making major contributions.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: BREAST LESION LOCALIZATION MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe breast lesion localization market accounts for the second-largest market share because major medical businesses are launching more products. For instance, Siemens Healthineers unveiled Mammovista B.smart on March 3, 2021, a new software programme streamlining the entire breast imaging reading process. Additionally, growing startup company investments in cancer treatment are boosting market revenue. Further, the German market of breast lesion localization held the largest market share, and the UK market of breast lesion localization was the fastest growing market in the European region
The Asia-Pacific Breast lesion localization Market is expected to grow at the fastest CAGR from 2023 to 2032 due to the cancer's prevalence. India has the highest national cancer mortality rates, according to the most recent study results. As breast cancer is the most common type of cancer among Indian women, women in their early 30s to 50s are at a significant risk of developing it. Moreover, China’s market of breast lesion localization held the largest market share, and the Indian market of breast lesion localization was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the breast lesion localization market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, breast lesion localization industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the breast lesion localization industry to benefit clients and increase the market sector. In recent years, the breast lesion localization industry has offered some of the most significant advantages to medicine. Major players in the market of breast lesion localization attempting to increase market demand by investing in research and development operations include D. Company (US), Cianna Medical (US), Cook Medical (US), Endomagnetics Ltd (UK), Health Beacon (Ireland), Intra medical imaging, Devicor Medical Products Inc (US), Somatex Medical Technologies GmbH (Germany), Surgiceye GmbH (Germany) and Ranfac Corporation (US).
Endomagnetics, Ltd. creates and manufactures medical products and devices. In place of radioactive materials, the company offers medical equipment for detecting and managing cancer. Based on a proprietary capability to identify magnetic elements inside the human body, Endomagnetics is a portfolio of medical technology products. In October 2020, a product called Magseed was introduced by Endomagnetics Ltd. It is implanted in the afflicted breast before surgery and uses a probe to show the surgeon precisely where the malignant tissue is situated.
Cook Group Incorporated is a privately held American business headquartered in Bloomington, Indiana, that specializes in producing medical equipment. In Forbes' 2008 America's Largest Private Companies, it came in at number 324.Its three primary divisions are Cook Medical, Cook Services, and Cook Properties. Each of the three divisions is composed of a number of subsidiary businesses. The medical division's flagship business, Cook Incorporated, was established in a Bloomington spare bedroom in 1963. Catheters, needles, and wire guides were among the first items produced by Cook Incorporated. The company now exports to 135 countries and produces more than 16,000 goods across 10 medical service areas.
September 2022: Temno Elite soft tissue biopsy system is now offered in the United States, according to Merit Medical Systems. This comprises soft tissue lesions in the lung, lymph nodes, kidney, liver, and other organs. The TEMNO, Achieve, and Tru-Cut device families are also included in the bigger portfolio that this single-use item is a part of.
August 2022: The Sparrow device, which is a part of the new SpeedBird line of vacuum-assisted Single Insertion/Multiple Collection (SIMC) Breast Biopsy devices, was first presented by TransMed7, LLC. The SpeedBird SIMC devices from TransMed7 are easy to use, need little setup, have great ultrasound visibility, are well tolerated by patients, and take only a short amount of time to complete each clinical procedure.
Wire-Guided Localization
Radioactive Seed Localization
Non-Radioactive Radar Localization
Magnetic Seed
Tumor Identification
Sentinel Lymph Node Identification
Hospitals and Clinics
Ambulatory Surgical Centers
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.54 billion |
| Market Size 2024 | USD 0.58 billion |
| Market Size 2032 | USD 1.0222 billion |
| Compound Annual Growth Rate (CAGR) | 7.21% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Usage, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | D. Company (US), Cianna Medical (US), Cook Medical (US), Endomagnetics Ltd (UK), Health Beacon (Ireland), Intra medical imaging, Devicor Medical Products Inc (US), Somatex Medical Technologies GmbH (Germany), Surgiceye GmbH (Germany) and Ranfac Corporation (US) |
| Key Market Opportunities | Increasing consumption of alcohol and a sedentary lifestyle causing obesity leads to cancer in a large number of populations |
| Key Market Dynamics | Rising incidence of breast cancer across the world |
Breast Lesion Localization Market Highlights:
Frequently Asked Questions (FAQ) :
The breast lesion localization market size was valued at USD 0.54 Billion in 2023.
The market is projected to grow at a CAGR of 7.21% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are D. Company (US), Cianna Medical (US), Cook Medical (US), Endomagnetics Ltd (UK), Health Beacon (Ireland), Intra medical imaging, Devicor Medical Products Inc (US), Somatex Medical Technologies GmbH (Germany), Surgiceye GmbH (Germany) and Ranfac Corporation (US).
The radioactive seed localization category dominated the market in 2023.
The hospitals and clinics category had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
